recombination repair


Also found in: Medical.

recombination repair

[rē‚käm·bə′nā·shən ri‚per]
(cell and molecular biology)
A repair mechanism involving exchange of correct for incorrect segments between two damaged deoxyribonucleic acid molecules.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Results from the trial have revealed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival with Lynparza compared with enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer selected for BRCA1/2 or ATM gene mutations, a subpopulation of homologous recombination repair gene mutations.
Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2.
Single nucleotide polymorphisms in the homologous recombination repair genes and breast cancer risk in Polish women.
It interacts with the BRCA1-associated RING finger domain protein (BARD1) (Jensen et al., 1998) which is required for ubiquitin ligase activity, the MRE11/RAD50/NBS1 (M/R/N) recombination repair complex, a putative DNA helicase BRCA1-associated C-terminal Helicase (BACH1) (Cantor et al., 2001), the CtBp-interacting protein CtIP (Kaelin et al., 1990) and RNA polymerase II (Scully et al., 2000).
They saw a presynaptic filament called Rad51 regulating the balance between one enzyme (Rad55-Rad57) that favors recombination repair and another (Srs2) that inhibits recombination repair.
Chen said the FANCI-FANCD2 pathway also is associated with the BRCA1 and BRCA2 pathways, which are involved in homologous recombination repair. Scientists know that homologous recombination repair is also required for the repair of DNA cross-links, but the exact details remain to be resolved, Chen said.
Release date- 07082019 - AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase III PROfound trial of LYNPARZA 300 mg (two 150 mg tablets) twice daily in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation (HRRm) and have failed prior treatment with new hormonal anticancer agents (second generation anti-androgen agent).
- British-Dutch pharmaceutical company AstraZeneca (OTC: AZNCF) AstraZeneca and US-based Merck (NYSE: MRK) have released positive results from the Phase 3 PROfound trial of Lynparza in men with metastatic castration-resistant prostate cancer (mCRPC) who have an homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal anticancer treatments (e.g.
(MYGN) announced that the AstraZeneca (AZN) /Merck (MRK) Phase III PROfound study demonstrated that men with metastatic castration-resistant prostate cancer who tested positive for germline and somatic mutations in homologous recombination repair genes benefitted from treatment with Lynparza, a novel PARP inhibitor.
Based on a scientifically selected panel of genes known to be involved in driving the Homologous Recombination Repair (HRR) process, the assay will be developed alongside the clinical programme for Lynparza.
Both sapacitabine and PARP inhibitors are more effective in cancer cells with BRCA mutations or other homologous recombination repair deficiencies.